5 completed, 1 active not recruiting, 1 recruiting, 1 terminated. 3 Phase 2, 3 Phase 3, 2 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Completed 2, Terminated 1 |
| Phase 3 | 3 | Active not recruiting 1, Completed 1, Recruiting 1 |
| Phase 1 | 2 | Completed 2 |
Follow BLU-5937: new trials by email Literature Review of BLU-5937 trials Research Report on BLU-5937
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A 24-Week Study of the Efficacy and Safety of BLU-5937 in Adults With Refractory Chronic Cough - China Extension BLU-5937, Placebo - Refractory Chronic Cough | Phase 3 | Recruiting | GlaxoSmithKline | 75 | 2025-11-21 | 2026-06-16 |
| A 24-Week Study of the Efficacy and Safety of BLU-5937 in Adults With Refractory Chronic Cough BLU-5937, Placebo - Cough, Refractory Chronic Cough | Phase 3 | Active not recruiting | Bellus Health Inc. - a GSK company | 997 | 2022-12-05 | 2026-07-14 |
| A 52-Week Study of the Efficacy and Safety of BLU-5937 in Adults With Refractory Chronic Cough BLU-5937, Placebo - Cough, Refractory Chronic Cough | Phase 3 | Completed | Bellus Health Inc. - a GSK company | 957 | 2022-10-25 | 2026-07-14 |
| Evaluation of the Pharmacokinetics and Safety of BLU-5937 in Healthy Adult Japanese and Caucasian Subjects BLU-5937 - Healthy | Phase 1 | Completed | Bellus Health Inc. - a GSK company | 34 | 2021-08-06 | 2023-12-22 |
| A Multiple-Dose Study of BLU-5937 in Chronic Pruritus Associated With Atopic Dermatitis BLU-5937, Placebo - Chronic Pruritus, Atopic Dermatitis | Phase 2 | Completed | Bellus Health Inc. - a GSK company | 142 | 2020-12-09 | 2022-10-17 |
| Evaluation of the Efficacy and Safety of BLU-5937 in Adults With Refractory Chronic Cough BLU-5937, Placebo - Refractory Chronic Cough | Phase 2 | Completed | Bellus Health Inc. - a GSK company | 310 | 2020-12-07 | 2021-12-13 |
| A Dose Escalation Study of BLU-5937 in Unexplained or Refractory Chronic Cough BLU-5937, Placebo - Chronic Refractory Cough | Phase 2 | Terminated | Bellus Health Inc. - a GSK company | 68 | 2019-07-10 | 2021-08-03 |
| BLU-5937: First-in-Human, Single and Multiple Doses Escalation, Safety, Tolerability, Pharmacokinetics and Food Effect BLU-5937, Placebo - Cough | Phase 1 | Completed | Bellus Health Inc. - a GSK company | 90 | 2018-07-09 | 2018-11-09 |
Chronic Cough (5) · Cough (4) · Respiration Disorders (2) · Respiratory Tract Diseases (2) · Signs and Symptoms, Respiratory (2) · Dermatitis, Atopic (1)
Bellus Health Inc. - a GSK company (7) · GlaxoSmithKline (1)
Canada (5) · United Kingdom (5) · United States (5) · China (2) · Czechia (2) · Germany (2) · Hungary (2) · India (2) · Poland (2) · Argentina (1) · Australia (1) · Belgium (1) · Colombia (1) · France (1) · Israel (1)
2019 (1)